Compare Stocks: ARTL, BON, BCDA, and ASBP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTL Artelo Biosciences	$0.78 +1.3%	$1.18	$0.71 ▼ $31.74	$1.82M	-0.11	1.94 million shs	51,192 shs
ASBP Aspire Biopharma	$7.05 +8.1%	$6.13	$3.31 ▼ $1,050.36	$9.17M	0.11	368,908 shs	5,069 shs
BCDA BioCardia	$0.83 +0.7%	$0.94	$0.75 ▼ $2.29	$9.44M	0.44	1.37 million shs	15,162 shs
BON Bon Natural Life	$1.06 -3.4%	$1.21	$1.08 ▼ $3.40	$8.64M	-0.17	35,665 shs	2,373 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTL Artelo Biosciences	0.00%	-24.51%	-30.63%	-77.29%	-97.48%
ASBP Aspire Biopharma	0.00%	-10.19%	+4.99%	+2.42%	-98.49%
BCDA BioCardia	0.00%	-3.05%	-31.32%	-25.75%	-61.31%
BON Bon Natural Life	0.00%	0.00%	-6.70%	-13.73%	-15.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTL Artelo Biosciences	$0.78 +1.3%	$1.18	$0.71 ▼ $31.74	$1.82M	-0.11	1.94 million shs	51,192 shs
ASBP Aspire Biopharma	$7.05 +8.1%	$6.13	$3.31 ▼ $1,050.36	$9.17M	0.11	368,908 shs	5,069 shs
BCDA BioCardia	$0.83 +0.7%	$0.94	$0.75 ▼ $2.29	$9.44M	0.44	1.37 million shs	15,162 shs
BON Bon Natural Life	$1.06 -3.4%	$1.21	$1.08 ▼ $3.40	$8.64M	-0.17	35,665 shs	2,373 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTL Artelo Biosciences	0.00%	-24.51%	-30.63%	-77.29%	-97.48%
ASBP Aspire Biopharma	0.00%	-10.19%	+4.99%	+2.42%	-98.49%
BCDA BioCardia	0.00%	-3.05%	-31.32%	-25.75%	-61.31%
BON Bon Natural Life	0.00%	0.00%	-6.70%	-13.73%	-15.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTL Artelo Biosciences	1.67	Reduce	$54.00	6,823.08% Upside
ASBP Aspire Biopharma	1.00	Sell	N/A	N/A
BCDA BioCardia	1.67	Reduce	$25.00	2,912.05% Upside
BON Bon Natural Life	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest ARTL, BON, BCDA, and ASBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	ASBP Aspire Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/26/2026	BON Bon Natural Life	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D)
6/24/2026	ARTL Artelo Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/9/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	($1.89) per share	N/A
ASBP Aspire Biopharma	$10K	916.50	N/A	N/A	($54.19) per share	-0.13
BCDA BioCardia	N/A	N/A	N/A	N/A	$0.08 per share	N/A
BON Bon Natural Life	$18.67M	0.46	N/A	N/A	$7.13 per share	0.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTL Artelo Biosciences	-$12.88M	-$32.74	N/A	N/A	N/A	N/A	-1,600.12%	-224.62%	8/12/2026 (Estimated)
ASBP Aspire Biopharma	-$24.48M	-$116.67	N/A	N/A	N/A	N/A	N/A	-398.04%	N/A
BCDA BioCardia	-$8.23M	-$0.91	N/A	N/A	N/A	N/A	-5,456.14%	-232.75%	8/10/2026 (Estimated)
BON Bon Natural Life	-$2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest ARTL, BON, BCDA, and ASBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ARTL Artelo Biosciences	-$0.72	N/A	N/A	N/A	N/A	N/A
8/10/2026	Q2 2026	BCDA BioCardia	-$0.19	N/A	N/A	N/A	N/A	N/A
5/15/2026	Q1 2026	ASBP Aspire Biopharma	N/A	-$20.57	N/A	-$20.57	N/A	$0.03 million
5/15/2026	Q1 2026	BCDA BioCardia	-$0.17	-$0.21	-$0.04	-$0.21	N/A	N/A
5/14/2026	Q1 2026	ARTL Artelo Biosciences	-$0.78	-$4.00	-$3.22	-$4.00	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTL Artelo Biosciences	N/A	N/A	N/A	N/A	N/A
ASBP Aspire Biopharma	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTL Artelo Biosciences	N/A	1.79	1.79
ASBP Aspire Biopharma	N/A	2.26	2.14
BCDA BioCardia	N/A	0.41	0.41
BON Bon Natural Life	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTL Artelo Biosciences	0.87%
ASBP Aspire Biopharma	19.17%
BCDA BioCardia	20.57%
BON Bon Natural Life	0.57%

Insider Ownership

Company	Insider Ownership
ARTL Artelo Biosciences	3.20%
ASBP Aspire Biopharma	5.80%
BCDA BioCardia	17.40%
BON Bon Natural Life	26.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTL Artelo Biosciences	5	2.33 million	2.26 million	Not Optionable
ASBP Aspire Biopharma	N/A	1.30 million	1.22 million	N/A
BCDA BioCardia	40	11.38 million	9.40 million	Optionable
BON Bon Natural Life	100	8.13 million	5.98 million	N/A

ARTL, BON, BCDA, and ASBP Headlines

Recent News About These Companies

Reviewing Bon Natural Life (NASDAQ:BON) & Advantage Solutions (NASDAQ:ADV)

August 2 at 3:16 AM | americanbankingnews.com

Bon Natural Life (BON) Holds Near Support After Modest Decline - Vol Target Rebalance

July 13, 2026 | donanimhaber.comD

BON CHARGE launches The BON CHARGE Method, an immersive guided wellness experience led by personal trainer to the stars

June 17, 2026 | globenewswire.com

BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives

March 31, 2026 | prnewswire.com

Bon Natural Life Ltd.

March 27, 2026 | barrons.com

BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market

February 19, 2026 | prnewswire.com

Bon Natural Life Deepens AI-Driven Biomanufacturing Push With Chang’an Pilot Joint Lab

February 17, 2026 | tipranks.com

BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

February 17, 2026 | prnewswire.com

Bon Natural Life announces $12M sales agreement for kombucha-inspired product

December 10, 2025 | msn.com

Bon Natural Life Secures $12 Million Deal with Qingshengyuan for Kombucha Products

December 10, 2025 | tipranks.com

BON Unveils Kombucha-Inspired Product, Inks $12 Million Strategic Sales Agreement with Qingshengyuan

December 10, 2025 | prnewswire.com

Bon Natural Life announces $26M cooperation agreement with Beijing Huahai Keyuan

November 25, 2025 | msn.com

Bon Natural Life Enters $26M Agreement for Tea Pigment Products in China

November 25, 2025 | tipranks.com

BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

November 25, 2025 | prnewswire.com

Bon Natural Life Appoints New CFO Amid Leadership Changes

November 14, 2025 | tipranks.com

Bon Natural Life files $500M mixed securities shelf

October 16, 2025 | msn.com

Be Wary Of Bon Natural Life (NASDAQ:BON) And Its Returns On Capital

October 1, 2025 | finance.yahoo.com

Bon Natural Life Reports Increased Profitability Despite Revenue Decline in Interim 2025 Results

September 29, 2025 | tipranks.com

BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products

September 9, 2025 | prnewswire.com

BON Announces Identification of Promising Weight-Managing Compounds from Tea via AI-Powered New Drug R&D Platform

September 2, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARTL, BON, BCDA, and ASBP Company Descriptions

Artelo Biosciences NASDAQ:ARTL

$0.78 +0.01 (+1.30%)

As of 11:05 AM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Aspire Biopharma NASDAQ:ASBP

$7.05 +0.53 (+8.13%)

As of 11:05 AM Eastern

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.

BioCardia NASDAQ:BCDA

$0.83 +0.01 (+0.70%)

As of 11:01 AM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Bon Natural Life NASDAQ:BON

$1.06 -0.04 (-3.36%)

As of 11:05 AM Eastern

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. The company provides personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; natural health supplements comprising powder drinks and bioactive food ingredient products primarily used as food additives; and nutritional supplements. Its products are principally used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is headquartered in Grand Cayman, the Cayman Islands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, BON, BCDA, and ASBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, BON, BCDA, and ASBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, BON, BCDA, and ASBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTL, BON, BCDA, and ASBP Company Descriptions

Artelo Biosciences NASDAQ:ARTL

Aspire Biopharma NASDAQ:ASBP

BioCardia NASDAQ:BCDA

Bon Natural Life NASDAQ:BON

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTL, BON, BCDA, and ASBP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTL, BON, BCDA, and ASBP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTL, BON, BCDA, and ASBP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTL, BON, BCDA, and ASBP Company Descriptions

Artelo Biosciences NASDAQ:ARTL

Aspire Biopharma NASDAQ:ASBP

BioCardia NASDAQ:BCDA

Bon Natural Life NASDAQ:BON

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools